PT  - JOURNAL ARTICLE
AU  - Lala, Anuradha
AU  - Johnson, Kipp W
AU  - Januzzi, James
AU  - Russak, Adam J
AU  - Paranjpe, Ishan
AU  - Zhao, Shan
AU  - Somani, Sulaiman
AU  - Vaid, Akhil
AU  - Chaudhry, Fayzan
AU  - Freitas, Jessica K De
AU  - Richter, Felix
AU  - Fayad, Zahi A
AU  - Pinney, Sean P.
AU  - Levin, Matthew
AU  - Charney, Alexander
AU  - Bagiella, Emilia
AU  - Narula, Jagat
AU  - Glicksberg, Benjamin S
AU  - Nadkarni, Girish
AU  - Mancini, Donna M.
AU  - Fuster, Valentin
AU  - ,
TI  - Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection
AID  - 10.1101/2020.04.20.20072702
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.20.20072702
4099  - http://medrxiv.org/content/early/2020/04/27/2020.04.20.20072702.short
4100  - http://medrxiv.org/content/early/2020/04/27/2020.04.20.20072702.full
AB  - Background The degree of myocardial injury, reflected by troponin elevation, and associated outcomes among hospitalized patients with Coronavirus Disease (COVID-19) in the US are unknown.Objectives To describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19.Methods Patients with COVID-19 admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value <0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospitals’ EHR.Results The median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. Even small amounts of myocardial injury (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were associated with death (adjusted HR: 1.77, 95% CI 1.39-2.26; P<0.001) while greater amounts (e.g. troponin I>0.09 ng/dL, n=530, 19.4%) were associated with more pronounced risk (adjusted HR 3.23, 95% CI 2.59-4.02).Conclusions Myocardial injury is prevalent among patients hospitalized with COVID-19, and is associated with higher risk of mortality. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation likely reflects non-ischemic or secondary myocardial injury.Unstructured Abstract Myocardial injury reflected as elevated troponin in Coronavirus Disease (COVID-19) is not well characterized among patients in the United States. We describe the prevalence and impact of myocardial injury among hospitalized patients with confirmed COVID-19 and troponin-I measurements within 24 hours of admission (N=2,736). Elevated troponin concentrations (normal <0.03ng/mL) were commonly observed in patients hospitalized with COVID-19, most often present at low levels, and associated with increased risk of death. Patients with cardiovascular disease (CVD) or risk factors for CVD were more likely to have myocardial injury. Troponin elevation likely reflects non-ischemic or secondary myocardial injury.Competing Interest StatementDisclosures/Conflict of Interest: Dr. James Januzzi is a Trustee of the American College of Cardiology, has received grant support from Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, MyoKardia and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, and Takeda. Dr. Sean Pinney has received consulting fees from Abbott, CareDx, Medtronic and Procyrion.Funding StatementThis work was Supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Mount Sinai Institutional Review Board (IRB) approved this research under a regulatory protocol allowing for analysis of patient-level COVID-19 data.AFatrial fibrillationCADcoronary artery diseaseCKDchronic kidney diseaseCOPDchronic obstructive pulmonary diseaseCOVID-19coronavirus disease 2019CVDcardiovascular diseaseDMdiabetes mellitusHFheart failureHTNhypertensionMSHSMount Sinai Health SystemSARS-CoV-2severe acute respiratory syndrome coronavirus-2